

Disparities in Access to Radiotherapy Among Hispanic/Latinx Populations in the United States

How Far Have We Left to Go?

Nicholas P. Verdini, BS,* Patricia Mae G. Santos, MD,*
Yorlenny M. Vicioso-Mora, MD, PhD,† Amanda Rivera, MD,‡
Carmen A. Perez, MD, PhD,§ and Shearwood McClelland III, MD||

Objectives: The Hispanic/Latinx population has consistently faced disparities in oncology access and outcomes with cancer being the leading cause of death in this population. We evaluate recent research in radiation therapy disparities among the Hispanic/Latinx population in the United States since our seminal analysis from 2017.

Methods: A PubMed literature search was conducted for articles published from January 2017 through March 2023. Four term combinations were utilized, including: (1) “Hispanic” and “Radiotherapy” and “Disparities”, (2) “Latino” and “Radiotherapy” and “Hispanic”, (3) “Hispanic” and “Radiation” and “Disparities”, and (4) “Latino” and “Radiation” and “Disparities.” Included studies were those taking place in the United States, examined radiation oncology care, and examined health disparities.

Results: Fifty-eight of 245 articles returned met inclusion criteria and spanned 6 disparity-types: (1) Stage at Presentation, (2) Time to Treatment Initiation & Completion, (3) Receipt of Treatment and Guideline-Concordant Care, (4) Geography, (5) Clinical Trial Access and (6) Insurance Barriers and Treatment Center Type. The most common disparity was receipt of treatment and guideline-concordant care (n=39 studies), demonstrating that the Hispanic/Latinx population was less likely to receive guideline-concordant treatment or treatment at all. In addition, studies identified disparities in time to treatment and completion (n=12), geography (n=5), clinical trial access (n=3), and insurance and treatment center access (n=5).

Conclusions: Disparities in radiotherapy access remain prominent for the Hispanic/Latinx population through a multitude of barriers, despite increasing interest in disparities research. Continued health care disparities research with tangible interventions are needed in radiation oncology to properly understand and address this problem.

Key Words: disparities, hispanic, latino, radiotherapy access, United States

(*Am J Clin Oncol* 2024;47:40–47)

From the *Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY; †Department of Radiation Oncology, Duke University, Durham, NC; ‡Department of Radiation Oncology, University of Miami, Miami, FL; §Department of Radiation Oncology, St. Jude Children’s Research Hospital, Memphis, TN; and ||Department of Radiation Oncology and Neurological Surgery, University Hospitals Seidman Cancer Center, Case Western Reserve, Cleveland, OH.

The authors declare no conflicts of interest.

Correspondence: Shearwood McClelland III, MD, Department of Radiation Oncology, University Hospitals Seidman Cancer Center 1100 Euclid Avenue, Lerner Tower Office Suite B161 Cleveland, OH 44106. E-mail: drwood@post.harvard.edu.

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

ISSN: 0277-3732/24/4701-0040

DOI: 10.1097/COC.0000000000001063

Cancer is the leading cause of death among Hispanic/Latinx populations in the United States, with 1 in 5 men and 1 in 7 women dying from cancer in 2016 to 2018.¹ Importantly, although cancer-related mortality has been generally decreasing across populations, this has not been exhibited among Hispanic individuals; mortality rate due to certain cancers and age groups have unfortunately been increasing in the Hispanic population.² In 2021, the US Hispanic/Latinx population comprised ~63 million individuals, up from 51 million in 2010—a 24% relative increase over the past decade, significantly outpacing the nation’s overall population growth rate of ~7%.³ As the Hispanic/Latinx population continues to grow, addressing barriers to cancer care delivery will be of increasing public health importance.

Radiation therapy (RT) is a mainstay of oncologic care and has been shown to significantly improve clinical outcomes across multiple disease sites. Several studies have shown that failure to timely receipt of RT, not only results in substandard care but may also harm survival.⁴ However, disparities in access to RT continue to persist. The Hispanic/Latinx population in the US faces multiple barriers in healthcare related to a complex intersection of disparities related to socioeconomic status, language barriers to preventative care,⁵ less availability of paid sick leave,^{6,7} higher rates of uninsurance,⁸ migration status,⁹ and more.

In 2017, we published an overview of disparities in access to radiation oncology care,¹⁰ in which we identified that Hispanic/Latinx patients were less likely to receive definitive radiation or receive any radiation at all in certain disease types. In this review, we conduct an updated analysis of recent research regarding disparities in access to RT in the US Hispanic/Latinx population. We explore the barriers to RT that currently exist for Hispanic/Latinx patients, highlight the most commonly identified barriers, and offer potential solutions for making radiation oncology care more equitable.

METHODS

A literature search was conducted through PubMed for articles published from January 2017 through March 2023. The following term combinations were utilized: (1) “Hispanic” and “Radiotherapy” and “Disparities”, (2) “Latino” and “Radiotherapy” and “Hispanic”, (3) “Hispanic” and “Radiation” and “Disparities”, and (4) “Latino” and “Radiation” and “Disparities.” All articles returned from each search were documented and duplicates were removed. After the initial search, studies were included for analysis if they met the following inclusion criteria: (1) The study took place in the United States; (2) The study analyzed disparities in radiation oncology care; and (3) The

study included an examination of health disparities in the Hispanic/Latinx population. Articles meeting criteria were then organized based on the major thematic categories that emerged.

RESULTS

A schematic detailing our article search is shown in Fig. 1. Of the 245 articles found on our initial search, 58 met criteria for study inclusion. Articles excluded were due to evaluation of the wrong patient population (n=24), not pertaining to RT (n=88), non-oncologic study (n=7), wrong focus (n=53), incorrect article type (n=6), and other (n=7). We organized included articles by disparity-type (n=6). A detailed list of findings and supporting articles is shown in Table 1.

Stage at Presentation

Stage at presentation was another common disparity evaluated. Although these articles did not directly address the connection of this to RT access, it is important to highlight this disparity as it may have important implications related to access. For instance, patients who present at later stages may require more intense treatment regimens or may have less treatment options available to them compared with if they presented earlier. Six of the identified articles addressed this disparity, with 4 identifying a disparity³²⁻³⁵ and 2 finding no relationship with the Hispanic population.^{36,37} One of the identified studies, by Moore et al,³⁴ identified that regardless of rural versus urban location, patients with breast cancer that identified as Hispanic were more likely to present with late-stage disease at diagnosis compared with non-hispanic white (NHW) patients (Hispanic-Urban: adjusted odds ratio [aOR] 1.25, Hispanic-Rural: aOR 1.75).

Time to Treatment Initiation and Completion

We identified 12 articles addressing disparities in time to initiate treatment, and complete treatment. Of the 12 articles identified, 10 had findings that indicate the existence of a

disparity for the Hispanic population in this area,¹¹⁻²⁰ whereas 2 did not.^{30,38}

Studies identified a longer time from presentation to first RT treatment for those with Hispanic ethnicity compared with Non-Hispanic patients. In a retrospective study of safety-net patients with breast cancer by Jaiswal et al,¹¹ they identified that being of Hispanic ethnicity (OR 3.38; 95% CI 1.41-8.12) and Non-English speaking (English-speaking OR 0.20; 95% CI 0.07-0.61) significantly increased the odds of experiencing a longer interval from presentation to treatment. Hutten and colleagues also evaluated time to treatment initiation disparities, evaluating the time to definitive-intent IMRT in 10 different cancer types. They demonstrated that Hispanic patients, among other minority groups, were significantly more likely to have delayed initiation of treatment for nearly all disease sites compared with NHW patients, with Hispanic patients having a median time to treatment initiation of 76 days compared with a median time of 67 days for NHW patients ($P < 0.01$).¹⁶

In addition to greater time to initiate treatment, it was also identified that Hispanic patients had greater amounts of time to complete RT.^{19,20} Lamm and colleagues conducted a retrospective study on patients undergoing breast conservation therapy for early-stage breast cancer, evaluating the timely completion of adjuvant radiation with hypofractionated and conventional regimens. They demonstrated that timely completion was significantly greater in those undergoing hypofractionated regimens compared with conventional (94.5% vs. 74.8%, $P < 0.0001$), and this was true in all racial/ethnic groups. However, in both regimens, Hispanic patients had lower odds of timely completion compared with White patients (hypofractionated OR = 0.842, convention OR = 0.821; $P < 0.0001$).

Receipt of Treatment and Guideline-concordant Care

Another disparity that was commonly assessed was the association between Hispanic ethnicity and receipt of any




FIGURE 1. Study Schematic.

TABLE 1. Articles Identifying Disparities Among the Hispanic Population

Disparity (n = number of articles identifying a disparity)	Summary finding	Articles with finding	Detailed findings
Time to treatment initiation and completion (n = 10)	Hispanic ethnicity is associated with greater time to treatment initiation	Jaiswal et al. 2018 ¹¹ JNCCN Anticancer Research 2022 ¹² Breast Cancer Research and Treatment Ramey et al. 2018 ¹⁴ Journal of GI Oncology Hutten et al. 2022 ¹⁵ JCO Oncology Practice Ramey et al. 2018 ¹⁶ Gynecologic Oncology Ostrom et al. 2021 ¹⁷ Journal of Neurooncology Krimphove et al. 2019 ¹⁸ Journal of Urology	Greater time to treatment initiation for Hispanic population: OR 3.38, 95% CI 1.41-8.12 Time to initiate treatment was 177.2 d for Hispanic population vs. NHW 136.9 d, $P < 0.01$ Hispanic ethnicity added 9.1 d to initiate RT, $P < 0.0001$ Greater time to treatment initiation for Hispanic population: RR 1.19, 95% CI 1.14-1.24 Time to initiate treatment was 76 d for Hispanic population vs. 67 d for Non-Hispanic, $P < 0.01$ Greater time to treatment initiation for Hispanic population: RR 1.19, 1.15-1.24. Time to treatment initiation was ~3 d longer compared with NHW ($P < 0.0001$). Mean time to treatment was longer at minority serving hospitals: 4.9 ± 2.2 d, $P = 0.024$.
	Hispanic ethnicity is associated with less timely treatment completion	Lamm et al. 2022 ¹⁹ Surgery J or Racial and Ethnic Disparities 2023 ²⁰	Hispanic ethnicity had lower odds of timely treatment completion vs. NHW: Hypofactionated RT OR 0.917 and Traditional RT OR 0.907, $P < 0.0001$. Time to treatment completion was higher in minority population *Hispanic data were combined with Black and Native American population
Receipt of Treatment / Standard Of Care (n = 24)	Hispanic ethnicity is associated with failure to initiate treatment	Parekh et al. 2018 ²¹ Breast Cancer Research and Treatment Bagley et al. 2020 ²² JAMA Network Open Lu et al. 2020 Journal of NeuroOncology Bordes et al. 2018 Journal of Racial and Ethnic Health Disparities Gray et al. 2017 European Urology Roche et al. 2018 Cancer Baig et al. 2021 Journal of the Pancreas Stenzel et al. Cancer Epidemiology Lee et al. 2017 Annals of Surgical Oncology Antebay et al. 2022 Annals of Surgical Oncology Swami et al. 2022 Prostate Cancer and Prostatic Diseases Seldon et al. 2021 JAMA Network Open Luo et al. 2021 Gynecologic Oncology Jacobs et al. 2017 Journal of Surgical Research Mantz et al. 2023 Journal of Racial and Ethnic Disparities Ostrom et al. 2021 Journal of NeuroOncology	Less likely to receive RT compared with Non-Hispanic patients: 85.3% vs. 90.2%, $P < 0.0001$. More likely to receive systemic therapy only (OR 1.36, $P = 0.001$) or no treatment (OR 1.36, $P < 0.001$). Less likely to receive RT compared with Non-Hispanic patients: OR 0.82, $P < 0.01$ Less likely to receive RT than Black and White patients: OR 0.78, 95% CI 0.72-0.85 Low-risk Hispanic patients more likely to be observed than receive definitive local therapy: aOR 1.08, $P = 0.04$. Non-White patients more likely to not receive any treatment (aOR 0.29). Non-White patients less likely to receive RT (aOR 0.55) Less likely to receive adjuvant RT ($P < 0.05$). Hispanic women had lowest frequency of receiving any radiation. More likely to not receive RT than NHW: 27.1% vs. 16.5%, $P < 0.05$. Less likely to receive neoadjuvant chemoradiation compared with NHW: OR 0.6. Lower odds of receiving adjuvant RT: OR 0.77, 95% CI 0.69-0.86. Among men with unfavorable-risk disease, Hispanic men were less likely to receive treatment* than NHW men White Hispanic young adults were less likely than Non-Hispanic young adults to receive RT: OR 0.53, 95% CI 0.36-0.78, $P = 0.002$ Less likely to receive adjuvant RT than NHW: OR 0.75, 95% CI 0.65-0.87. White patients were more likely to receive RT than Black and Hispanic patients ($P = 0.01$). Failure to initiate treatment was 29.3% relatively greater for Black, Hispanic, and Native American patients than for White and Asian patients. Less likely to receive RT and chemotherapy compared with NHW patients.
	Hispanic ethnicity is associated with decreased receipt of	Kaspers et al. 2020 AJOG Lee et al. 2018 Cancer Causes and Control Krimphove et al.	Lower odds of receiving guideline-concordant care compared with NHW: OR 0.90, 95% CI

TABLE 1. (continued)

Disparity (n = number of articles identifying a disparity)	Summary finding	Articles with finding	Detailed findings
	guideline-concordant treatment	2019 Journal of Urology Gray et al. 2017 European Urology Vassantachart et al. 2022 Journal of Gastrointestinal Oncology Blom et al. 2020 Annals of the American Thoracic Society Dressler et al. 2019 Neuro-Oncology Practice Uppal et al. 2017 Obstetrics and Gynecology Perlow et al. 2019 Laryngoscope	0.83-0.97 Less than 2/3rds of Black and Hispanic men received EBRT that was compliant with all available quality measures (P=0.012) Treatment at minority serving hospitals was associated with decreased odds of definitive treatment (OR 0.73, P<0.001) Less likely to receive radical prostatectomy instead of RT than NHW: aOR 0.92, P<0.001. Less likely to receive standard treatment compared with NHW: OR 0.86, 95% CI 0.80-0.92 Less likely to receive guideline-concordant care than NHW: aOR 0.94 Less odds of receiving standard of care treatment than Non-Hispanics: OR 0.87, P=0.0002. Less likely to receive guideline-concordant care: 58.4% for NHW, 53% for NHB, and 51.5% for Hispanic (P<0.001). Less likely to receive follow-up care: OR 0.10, P = 0.044
Geography (n = 4)	Regardless of location, Hispanic ethnicity was associated with less likelihood of receiving treatment	Moore et al. 2023 Breast Cancer Research and Treatment Lu et al. 2020 ²³ Journal of NeuroOncology	Less likely to receive RT compared with NHW-Urban women: Hispanic-Urban aOR: 1.19, Hispanic-Rural aOR: 1.25 Less likely to receive RT compared with Non-Hispanic patients: OR: 0.82. Significantly lower in Mid-Atlantic: OR 0.77.
	Hispanic patients had greater distance to travel to RT treatment center	Greer et al. 2021 IJROB	Required to travel further to nearest RT center: 1.11 times farther than Non-Hispanic patients (95% CI 1.06-1.11)
	Hispanic patients are less likely to travel far distances for treatment, worsening outcomes.	Graboyes et al. 2018 ²⁴ Cancer	Less likely to travel far distances for tx (P<0.001). Traveling long distance associated with improved OS (aHR:0.93)
Clinical trial access (n=3)	Hispanic patients are less likely to be invited to participate in clinical trials	Patel et al. 2020 ²⁵ Breast Cancer Research and Treatment	Less likely to be invited to participate: aOR 0.23, 95% CI 0.08-0.64
	Hispanic patients are underrepresented in oncology trials	Javier-DesLoges et al. 2022 ²⁶ Cancer Ladbury et al. 2022 ²⁷ Brachytherapy	Underrepresented in oncology trials: Colorectal OR 0.74, Lung OR 0.66, and Prostate 0.58 P<0.001. Underrepresented in oncology trials: Proportion of Hispanic pts enrolled in brachytherapy trials was significantly lower than general population (-1.05%).
Insurance and treatment center type (n=6)	Hispanic patients are more likely to be uninsured	Stenzel et al. 2019 ²⁸ Cancer Epidemiology	Statistically highest frequency of being medically uninsured
	Hispanics with private insurance shortened time to treatment	Hutten et al. 2022 ¹⁶ JCO Oncology Practice	NHW, Hispanic, and Asian patients with private insurance had shorter median time to treatment initiation than those with Medicare: P<0.01
	When stratifying by insurance, Hispanic patients still receive RT less often	Du et al. 2022 ²⁹ Cancer Treatment and Research Communications	When stratified by health insurance, Hispanic patients with private insurance were less likely to receive RT than White patients: aOR 0.82, 95 CI 0.71-0.94
	Safety net hospital oncology patients are more likely to be Hispanic	Perlow et al. 2018 ³⁰ Otolaryngology Head and Neck Surgery Patel et al. 2022 ³¹ Neuro-Oncology Practice	Compared with a private hospital, more patients at the safety net hospital were Hispanic: 34.4% vs. 69.6%, P<0.001. Patients at the safety net hospital were more commonly Hispanic and more likely received whole-brain RT (35% vs. 16%, P=0.001)
Stage at presentation (n=4)	Hispanic patients are more likely to present with later stage disease	Swami et al. 2022 Prostate Cancer and Prostatic Disease	Greater odds of presenting with higher-risk cancer compared with white men: aOR 1.18

TABLE 1. (continued)

Disparity (n = number of articles identifying a disparity)	Summary finding	Articles with finding	Detailed findings
		Nnorom et al. 2022 ³² <i>The American Surgeon</i>	More likely to present with distant disease compared with white patients: 5% vs. 3%, $P < 0.001$
		Jacobs et al. 2017 ³³ <i>Journal of Surgical Research</i>	Significantly more likely to present with advanced stage disease than white patients, $P < 0.001$
		Moore et al. 2023 ³⁴ <i>Breast Cancer Research and Treatment</i>	Hispanic patients in rural and urban areas more likely to present with late-stage diagnosis: Hispanic-Urban aOR: 1.25, Hispanic-Rural aOR: 1.17 compared with NH white patients

Articles are organized by the disparity in which they address. Only articles that identified a disparity for the Hispanic/Latinx population are included in this table. aOR indicates adjusted odds ratio; NHW, non-hispanic white; OR, odds ratio; RR, relative risk; RT, radiation therapy.

treatment, as well as treatment concordant with national guidelines. We identified 39 articles addressing this disparity. Of the 39 articles, 15 studies found that patients who identified as having Hispanic/Latinx ethnicity were significantly more likely to not receive radiation treatment^{17,18,20,21,23,28,33,35,39–45} for prostate cancer (n = 4 articles), glioblastoma (n = 2), breast cancer (n = 1), anaplastic thyroid cancer (n = 1), pancreatic cancer (n = 1), gynecologic cancer (n = 2), rectal cancer (n = 1), NSCLC (n = 1), and pediatric sarcoma (n = 1). In addition, 10 articles revealed that Hispanic patients are more likely to receive non-guideline-concordant care,^{22,46–54} and this was identified in prostate cancer (n = 2 articles), gynecologic cancer (n = 2), rectal cancer (n = 1), head and neck cancer (n = 1), lung (n = 1), sarcoma (n = 1), and glioblastoma (n = 1),

Geography

Five articles evaluated disparities regarding geography, including length of travel for treatment. Of the 5 articles identified, 4 identified a disparity for the Hispanic population^{23,24,34,55} and 1 did not.⁵⁶ These articles found that regardless of location, Hispanic ethnicity was associated with less likelihood of receiving treatment,^{23,34} that Hispanic patients had greater distance to travel to an RT treatment center,⁵⁵ and that Hispanic patients are less likely to travel far distances for treatment, worsening outcomes.²⁴

Clinical Trial Access

We identified 3 articles that evaluated Hispanic patients' access to and representation in oncologic clinical trials.^{25–27} All articles evaluated identified a disparity for the Hispanic population. Patel et al²⁵ identified that Hispanic patients with newly diagnosed breast cancer are less likely to be invited to participate in clinical trials (aOR 0.23, 95% CI 0.08–0.64), whereas Javier-DesLoges²⁶ and Ladbury²⁷ identified a lack of Hispanic representation. Javier-DesLoges et al. demonstrated that Hispanic patients were likely to be underrepresented in oncology trials for colorectal (OR 0.74, $P < 0.001$), lung (OR 0.66, $P < 0.001$), and prostate (OR 0.58, $P < 0.001$) disease sites. Ladbury and colleagues evaluated Hispanic representation in brachytherapy trials specifically, demonstrating that the proportion of Hispanic patients enrolled in brachytherapy trials was significantly less than the general population.

Insurance Barriers and Treatment Center Type

Five articles were identified that addressed insurance barriers, and the type of treatment center that care was received at.^{16,28,29,31,49} Authors identified that the Hispanic population was more commonly uninsured (4.4% vs. 1.4% for NHW patients, $P < 0.0001$),²⁸ that those with private insurance (vs. Medicare) had shorter time to treatment initiation,¹⁶ that oncology patients at safety net hospitals were more often Hispanic (69% vs. 34% at private hospital, $P < 0.001$),^{30,31} and that regardless of insurance status, Hispanic patients still receive RT less often than White patients (aOR 0.82, 95 CI 0.71–0.94).²⁹

DISCUSSION

Disparities for the Hispanic/Latinx population continue to be prevalent in radiation oncology care. In this review, we identified an array of disparities that the Hispanic/Latinx population continues to face in this area of medicine. Increased time to treatment initiation, decreased access to quality care, lower likelihood of receiving RT, increased likelihood of receiving non-guideline concordant RT, insurance status, worse stage at presentation, and low representation and access to clinical trials work synergistically to create inequitable access in radiation oncology for the Hispanic/Latinx population.

The reasons for these disparities are likely multifactorial. In 2020, the median household income in Hispanic/Latinx households working full-time was \$55,321, compared with \$74,912 for non-Hispanic households.⁵⁷ Income plays a major role in advancing disparities in health care in every facet, including access to health insurance,⁵⁸ transportation to healthcare appointments,⁵⁹ treatment center type,⁶⁰ increased morbidities,⁶¹ etc. This also leads to a decrease in quality of life, which has been shown to result in worse radiation treatment adherence.⁶²

Physician-patient ethnic non-concordance may also play a significant role in the disparities identified. Prior studies have shown that racial/ethnic concordance of physician-patient dyads is associated with improved patient satisfaction and better clinical outcomes. This may be due to satisfaction of care resulting in increased compliance to treatment recommendations and follow-up, as well as more effective communication regarding ongoing symptoms.^{63,64} Diversity in the radiation oncology workforce is significantly lacking,^{65–67} with the specialty ranking in the lower third of representation among 33 medical specialties.⁶⁸ Recent efforts have been made to increase the diversity of the radiation




FIGURE 2. Number of articles evaluating disparities to radiation therapy in the Hispanic/Latinx population by year: For each year, the number of full-text research articles returned by PubMed for our primary search terms are displayed, with a linear trend line illustrating the trend in article numbers from January 2013 to early September 2023. Abstracts were not included. [full color online](#)

oncology workforce. For instance, Nead et al⁶⁹ details methods to improve recruitment to residency programs as an ideal target to address this issue as residency is the entry point into the specialty. The AAMC, along with participating medical schools, have also made substantial effort to increase the diversity of those attending,⁷⁰ which can in-turn increase the diversity of our workforce. However, the future is uncertain as to how the recent Supreme Court decision to prevent racial/ethnic-informed admissions will impact the diversity of the future physician workforce.

Language is another component likely to widen the gap in equitable radiation care. The HOLA RCT by Sieble et al.⁷¹ demonstrated that compared with patients receiving care through professional interpretive services, patients receiving care in direct Spanish had significantly improved satisfaction, communication, time spent with physicians, perceived physician empathy, and confidence in their physician's abilities. With 2019 Census data demonstrating that 71.1% of Hispanic/Latinx families speaking a language other than English at home,⁵⁷ language is an important consideration when evaluating and addressing disparities in radiation care.

Physician implicit bias is another key player in further disparaging the Hispanic/Latinx population. In oncology, implicit bias has been shown to result in less patient-centered communication and decreased memory of the details of the visit. In addition, physicians are less likely to offer clinical trials to minorities due to bias and this has negative impacts on representation and availability of trials to the Hispanic/Latinx population. Efforts to increase clinical trial recruitment of minorities are necessary. Methods focused on addressing disparities to trial recruitment and access, such as communication in community centers as demonstrated by Vicioso et al⁷² may aid in closing this gap.

With more literature being published that supports the gaps in equitable access to radiation that we know to exist, there is more opportunity for studies to evaluate tangible and evidence-based strategies to close these gaps. The number of research articles evaluating disparities for the Hispanic population in this field have substantially increased over the years (Fig. 2), pointing to the growing acknowledgment and understanding of these inequities, as well as demonstrating the expanding resource of evidence to support interventions.

Limitations

There are several limitations to this study. This study design is not a systematic review, and therefore was not subject to the same requirements necessary to producing a comprehensive review. Nonetheless, we provide a summary of recent literature addressing this topic. In addition, our literature search was limited to 4 combinations of phrases and our results may not be comprehensive in the amount and type of disparities facing this population.

CONCLUSION

This review highlights the significant number of disparities still facing the Hispanic/Latinx population in terms of RT access and demonstrates the amount of work that is still left to be done. Although research continues to grow a greater interest in identifying disparities facing the Hispanic/Latinx communications, further resources should be invested in developing tangible methods to creating more equitable access to RT for this population.

REFERENCES

1. American Cancer Society Cancer Facts & Figures for Hispanics/Latinos 2018-2020.
2. Pompa IR, Ghosh A, Bhat S, et al. US Cancer Mortality Trends Among Hispanic Populations From 1999 to 2020. *JAMA Oncol*. 2023;9:1090.
3. Krogstad J, Passel Jeffrey, Noe-Bustamante Luis Key facts about U.S. Latinos for National Hispanic Heritage Month. Pew Research Center. 2023. <https://www.pewresearch.org/short-reads/2022/09/23/key-facts-about-u-s-latinos-for-national-hispanic-heritage-month/>
4. Dayan GS, Bahig H, Johnson-Obaseki S, et al. Oncologic significance of therapeutic delays in patients with oral cavity cancer. *JAMA Otolaryngol Head Neck Surg*. 2023:e231936. doi:10.1001/jamaoto.2023.1936.
5. Hall II, Rim SH, Dasari S. Preventive care use among Hispanic adults with limited comfort speaking English: an analysis of the Medical Expenditure Panel Survey data. *Prev Med*. 2022;159:107042.
6. Terceira Berdahl PD *Prevalence of Paid Sick Leave Among Wage Earners*. 2021. https://meps.ahrq.gov/data_files/publications/rf47/rf47.pdf

7. Peipins LA, Soman A, Berkowitz Z, et al. The lack of paid sick leave as a barrier to cancer screening and medical care-seeking: results from the National Health Interview Survey. *BMC Public Health*. 2012;12:520.
8. OoHP HHS. *Health Insurance Coverage and Access to Care Among Latinos: Recent Trends and Key Challenges* 2021. https://aspe.hhs.gov/sites/default/files/documents/68c78e2fb15209dd191cf9b0b1380fb8/ASPE_Latino_Health_Coverage_IB.pdf
9. Martinez-Donate AP, Verdecias N, Zhang X, et al. Health Profile and Health Care Access of Mexican Migration Flows Traversing the Northern Border of Mexico. *Med Care*. 2020;58:474–482.
10. McClelland S 3rd, Perez CA. The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the United States-part 3: Hispanic-American patients. *Adv Radiat Oncol*. 2018;3:93–99.
11. Jaiswal K, Hull M, Furniss AL, et al. Delays in diagnosis and treatment of breast cancer: a safety-net population profile. *J Natl Compr Canc Netw*. 2018;16:1451–1457.
12. Sukniem K, Kasbi AA, Ashary MA, et al. Disparities in time to treatment for breast cancer. *Anticancer Res*. 2022;42:5813–5818.
13. Verdine CG, Bayron JA, Chang C, et al. A tool to predict disparities in the timeliness of surgical treatment for breast cancer patients in the USA. *Breast Cancer Res Treat*. 2022;191:513–522.
14. Ramey SJ, Asher D, Kwon D, et al. Delays in definitive cervical cancer treatment: an analysis of disparities and overall survival impact. *Gynecol Oncol*. 2018;149:53–62.
15. Ramey SJ, Rich BJ, Kwon D, et al. Demographic disparities in delay of definitive chemoradiation for anal squamous cell carcinoma: a nationwide analysis. *J Gastrointest Oncol*. 2018;9:1109–1126.
16. Hutten RJ, Weil CR, Gaffney DK, et al. Racial and ethnic health disparities in delay to initiation of intensity-modulated radiotherapy. *JCO Oncol Pract*. 2022;18:e1694–e1703.
17. Ostrom QT, Krebs HL, Patil N, et al. Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US. *J Neurooncol*. 2021;152:603–615.
18. Krimphove MJ, Fletcher SA, Cole AP, et al. Quality of care in the treatment of localized intermediate and high risk prostate cancer at minority serving hospitals. *J Urol*. 2019;201:735–741.
19. Lamm R, Woodward SG, Varshney K, et al. A comparison of timely completion of hypofractionated and traditional adjuvant radiation therapy in early-stage breast cancer: evidence of impact on reducing racial and socioeconomic disparities. *Surgery*. 2022;172:31–40.
20. Mantz CA, Thaker NG, Deville C Jr, et al. A medicare claims analysis of racial and ethnic disparities in the access to radiation therapy services. *J Racial Ethn Health Disparities*. 2023;10:501–508.
21. Parekh A, Fu W, Hu C, et al. Impact of race, ethnicity, and socioeconomic factors on receipt of radiation after breast conservation surgery: analysis of the national cancer database. *Breast Cancer Res Treat*. 2018;172:201–208.
22. Bagley AF, Anscher MS, Choi S, et al. Association of sociodemographic and health-related factors with receipt of nondefinitive therapy among younger men with high-risk prostate cancer. *JAMA Netw Open*. 2020;3:e201255.
23. Lu VM, Shah AH, Eichberg DG, et al. Geographic disparities in access to glioblastoma treatment based on Hispanic ethnicity in the United States: Insights from a national database. *J Neurooncol*. 2020;147:711–720.
24. Graboyes EM, Ellis MA, Li H, et al. Racial and ethnic disparities in travel for head and neck cancer treatment and the impact of travel distance on survival. *Cancer*. 2018;124:3181–3191.
25. Patel MA, Shah JL, Abrahamse PH, et al. A population-based study of invitation to and participation in clinical trials among women with early-stage breast cancer. *Breast Cancer Res Treat*. 2020;184:507–518.
26. Javier-DesLoges J, Nelson TJ, Murphy JD, et al. Disparities and trends in the participation of minorities, women, and the elderly in breast, colorectal, lung, and prostate cancer clinical trials. *Cancer*. 2022;128:770–777.
27. Ladbury C, Liu J, Novak J, et al. Age, racial, and ethnic disparities in reported clinical studies involving brachytherapy. *Brachytherapy*. 2022;21:33–42.
28. Stenzel AE, Buas MF, Moysich KB. Survival disparities among racial/ethnic groups of women with ovarian cancer: An update on data from the Surveillance, Epidemiology and End Results (SEER) registry. *Cancer Epidemiol*. 2019;62:101580.
29. Du XL, Song L. Racial disparities in treatments and mortality among a large population-based cohort of older men and women with colorectal cancer. *Cancer Treat Res Commun*. 2022;32:100619.
30. Perlow HK, Ramey SJ, Silver B, et al. Assessment of oropharyngeal and laryngeal cancer treatment delay in a private and safety net hospital system. *Otolaryngol Head Neck Surg*. 2018;159:484–493.
31. Patel AM, Ali O, Kainthla R, et al. Primary central nervous system lymphoma: a real-world comparison of therapy access and outcomes by hospital setting. *Neurooncol Pract*. 2022;9:183–192.
32. Nnorom SO, Baig H, Akinyemi OA, et al. Persistence of disparity in thyroid cancer survival after adjustments for socioeconomic status and access. *Am Surg*. 2022;88:1484–1489.
33. Jacobs AJ, Lindholm EB, Levy CF, et al. Racial and ethnic disparities in treatment and survival of pediatric sarcoma. *J Surg Res*. 2017;219:43–49.
34. Moore JX, Andrzejak SE, Jones S, et al. Exploring the intersectionality of race/ethnicity with rurality on breast cancer outcomes: SEER analysis, 2000-2016. *Breast Cancer Res Treat*. 2023;197:633–645.
35. Swami N, Baez YA, Franco I, et al. Localized prostate cancer disparities in risk group at presentation and access to treatment for Hispanic men. *Prostate Cancer Prostatic Dis*. 2023;26:309–316.
36. McDermott JD, Eguchi M, Morgan R, et al. Elderly Black non-Hispanic patients with head and neck squamous cell cancer have the worst survival outcomes. *J Natl Compr Canc Netw*. 2020;19:57–67.
37. Beaulieu-Jones BR, Shewmaker G, Fefferman A, et al. Mitigating disparities in breast cancer treatment at an academic safety-net hospital. *Breast Cancer Res Treat*. 2023;198:597–606.
38. Roy M, Finch L, Kwon D, et al. Factors contributing to delays in initiation of front-line cervical cancer therapy: disparities in a diverse south Florida population. *Int J Gynecol Cancer*. 2022;32:1387–1394.
39. Lee DJ, Zhao Z, Huang LC, et al. Racial variation in receipt of quality radiation therapy for prostate cancer. *Cancer Causes Control*. 2018;29:895–899.
40. des Bordes JKA, Lopez DS, Swartz MD, et al. Sociodemographic disparities in cure-intended treatment in localized prostate cancer. *J Racial Ethn Health Disparities*. 2018;5:104–110.
41. Chau B, Ituarte PH, Shinde A, et al. Disparate outcomes in nonsmall cell lung cancer by immigration status. *Cancer Med*. 2021;10:2660–2667.
42. Roche AM, Fedewa SA, Shi LL, et al. Treatment and survival vary by race/ethnicity in patients with anaplastic thyroid cancer. *Cancer*. 2018;124:1780–1790.
43. Baig MZ, Filkins A, Khan M, et al. Survival benefits and disparities in adjuvant radiation therapy for patients with pancreatic cancer. *JOP*. 2021;22:36–41.
44. Lee DY, Teng A, Pedersen RC, et al. Racial and socioeconomic treatment disparities in adolescents and young adults with stage II-III rectal cancer. *Ann Surg Oncol*. 2017;24:311–318.
45. Luo LY, Aviki EM, Lee A, et al. Socioeconomic inequality and omission of adjuvant radiation therapy in high-risk, early-stage endometrial cancer. *Gynecol Oncol*. 2021;161:463–469.
46. Kaspers M, Llamocca E, Quick A, et al. Black and Hispanic women are less likely than white women to receive guideline-concordant endometrial cancer treatment. *Am J Obstet Gynecol*. 2020;223:398 e1–398 e18.
47. Gray PJ, Lin CC, Cooperberg MR, et al. Temporal trends and the impact of race, insurance, and socioeconomic status in the management of localized prostate cancer. *Eur Urol*. 2017;71:729–737.

48. Vasantachart A, Marietta M, Mehta S, et al. Racial disparities and standard treatment in locally advanced rectal cancer: a National Cancer Database study. *J Gastrointest Oncol*. 2022;13:2922–2937.
49. Perlow HK, Ramey SJ, Cassidy V, et al. Disparities in adherence to head and neck cancer follow-up guidelines. *Laryngoscope*. 2019;129:2303–2308.
50. Anteby R, Blaszkowsky LS, Hong TS, et al. Disparities in receipt of adjuvant therapy after upfront surgical resection for pancreatic ductal adenocarcinoma. *Ann Surg Oncol*. 2023;30:2473–2481.
51. Blom EF, Ten Haaf K, Arenberg DA, et al. Disparities in receiving guideline-concordant treatment for lung cancer in the United States. *Ann Am Thorac Soc*. 2020;17:186–194.
52. Seldon C, Shrivastava G, Al-Awady A, et al. Variation in management of extremity soft-tissue sarcoma in younger vs older adults. *JAMA Netw Open*. 2021;4:e2120951.
53. Dressler EV, Liu M, Garcia CR, et al. Patterns and disparities of care in glioblastoma. *Neurooncol Pract*. 2019;6:37–46.
54. Uppal S, Chapman C, Spencer RJ, et al. Association of hospital volume with racial and ethnic disparities in locally advanced cervical cancer treatment. *Obstet Gynecol*. 2017;129:295–304.
55. Greer MD, Amiri S, Denney JT, et al. Disparities in access to radiation therapy facilities among American Indians/Alaska Natives and Hispanics in Washington State. *Int J Radiat Oncol Biol Phys*. 2022;112:285–293.
56. LaVigne AW, DeWeese TL, Wright JL, et al. Radiotherapy deserts: the impact of race, poverty, and the rural-urban continuum on density of providers and the use of radiation therapy in the US. *Int J Radiat Oncol Biol Phys*. 2023;116:17–27.
57. Services USDoHaH. Profile: Hispanic/Latino Americans. <https://minorityhealth.hhs.gov/omh/browse.aspx?vl=3&lvlid=64#:~:text=Among%20full%2Dtime%20year%2Dround,U.S.%20Bureau%20of%20Labor%20Statistics>
58. DeVoe JE, Tillotson CJ, Marino M, et al. Trends in type of health insurance coverage for US Children and Their Parents, 1998–2011. *Acad Pediatr*. 2016;16:192–199.
59. Syed ST, Gerber BS, Sharp LK. Traveling towards disease: transportation barriers to health care access. *J Community Health*. 2013;38:976–993.
60. Omega T, Duell EJ, Shi X, et al. Race versus place of service in mortality among medicare beneficiaries with cancer. *Cancer*. 2010;116:2698–2706.
61. O'Connor JM, Sedghi T, Dhodapkar M, et al. factors associated with cancer disparities among low-, medium-, and high-income US counties. *JAMA Netw Open*. 2018;1:e183146.
62. Yoder AK, Dong E, Yu X, et al. Effect of quality of life on radiation adherence for patients with cervical cancer in an urban safety net health system. *Int J Radiat Oncol Biol Phys*. 2023;116:182–190.
63. Takeshita J, Wang S, Loren AW, et al. Association of racial/ethnic and gender concordance between patients and physicians with patient experience ratings. *JAMA Netw Open*. 2020;3:e2024583.
64. Shen MJ, Peterson EB, Costas-Muniz R, et al. The effects of race and racial concordance on patient-physician communication: a systematic review of the literature. *J Racial Ethn Health Disparities*. 2018;5:117–140.
65. McClelland S III, Huang CC, Griffith KA, et al. Composition of the current academic radiation oncology workforce in comprehensive cancer centers. *JCO Oncol Pract*. 2022;18:e740–e747.
66. Deville C Jr, Cruickshank I Jr, Chapman CH, et al. I Can't Breathe: The Continued Disproportionate Exclusion of Black Physicians in the United States Radiation Oncology Workforce. *Int J Radiat Oncol Biol Phys*. 2020;108:856–863.
67. Duma N, Velazquez AI, Franco I, et al. Donde Estan? Latinx/Hispanic Representation in the Oncology Workforce: Present and Future. *JCO Oncol Pract*. 2022;18:388–395.
68. Mattes MD, Deville C Jr, Vega RBM, et al. Demographics of ASTRO Student Members and Potential Implications for Future U.S. Radiation Oncology Workforce Diversity. *Adv Radiat Oncol*. 2022;7:100834.
69. Nead KT, Linos E, Vapiwala N. Increasing diversity in radiation oncology: a call to action. *Adv Radiat Oncol*. 2019;4:226–228.
70. Colleges AoAM. Advancing Diversity, Equity, and Inclusion in Medical Education. September 8th, 2023. <https://www.aamc.org/about-us/equity-diversity-inclusion/advancing-diversity-equity-and-inclusion-medical-education>
71. Seible DM, Kundu S, Azuara A, et al. the influence of patient-provider language concordance in cancer care: results of the hispanic outcomes by language approach (HOLA) randomized trial. *Int J Radiat Oncol Biol Phys*. 2021;111:856–864.
72. Ledesma Vicioso N, Lin D, Gomez DR, et al. Implementation strategies to increase clinical trial enrollment in a community-academic partnership and impact on hispanic representation: an interrupted time series analysis. *JCO Oncol Pract*. 2022;18:e780–e785.